Impact of allopurinol on metabolic acidosis in patients with chronic kidney disease; a randomized controlledtrial

Introduction: chronic kidney disease (ckd) is a disabling disease with multiplecomplications, like, increased serum levels of uric acid due to glomerular filtration rate (gfr)impairment.objectives: this study was designed to evaluate the effect of allopurinol on metabolic acidosisin patients with renal failure.patients and methods: this is a randomized controlled-trial study on 50 patients with ckdstage ii-iv, who referred to qaem and montaserieh hospitals in mashhad. patients wereselected and randomly divided into two equal groups of 25 subjects. in addition to standardtreatments, the intervention group received 100 mg allopurinol tablet for three months andthe control group received placebo. demographic data were obtained from each individual.serum uric acid level, creatinine, blood ph and bicarbonate levels were assessed at theinitiation of treatment and at the end of the third month.results: the mean age of patients was 54.04±12.62 years. allopurinol administration resultedin a significant increase of serum bicarbonate levels and ph (p < 0.001 for each) comparedto the control group. a significant reduction in uric acid (p < 0.05) and an increase in gfr(p < 0.05) was observed in both groups.conclusion: allopurinol could ameliorate metabolic acidosis, glomerular filtration and uricacid in patients with ckd.trial registration: this study was registered in iranian registry of clinical trial (identifier:irct2016122731604n1; https://irct.ir/trial/24831; registration date: 2017-08-05).